<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="16440">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01656109</url>
  </required_header>
  <id_info>
    <org_study_id>HIV-NAT 146</org_study_id>
    <nct_id>NCT01656109</nct_id>
  </id_info>
  <brief_title>Atazavanir/Ritonavir-based HAART in Children</brief_title>
  <official_title>The Study of Atazavanir/Ritonavir-based HAART in Thai HIV-infected Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The HIV Netherlands Australia Thailand Research Collaboration</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>amfAR and Treat Asia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Health Security Office, Thailand</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Thai Government Pharmaceutical Organization (GPO)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The HIV Netherlands Australia Thailand Research Collaboration</source>
  <oversight_info>
    <authority>Thailand: Ethical Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There are no data on efficacy, safety and pharmacokinetics of ATV/r-based HAART in
      HIV-infected Asian children. Therefore, the investigators aim to evaluate the
      pharmacokinetics, efficacy and safety of ATV/r-based HAART in Thai HIV-infected children.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Non-nucleoside reverse transcriptase inhibitor (NNRTI)-based HAART have been commonly
      prescribed as the first-line HAART for HIV-infected children in resource-limited settings.
      Protease inhibitor (PI)-based HAART are the recommended second-line regimen after failing
      NNRTI-based HAART. The most commonly used PI in Thailand is lopinavir/ritonavir (LPV/r).
      However, the metabolic complications of lopinavir/ritonaive (LPV/r) such as hyperlipidemia
      and lipodyrtrophy are common and a concern for HIV-infected children as it may contribute to
      the development of cardiovascular disease in the longer term. There are data on efficacy,
      safety and pharmacokinetics of ATV/r-based HAART in HIV-infected adults but none in
      children. Furthermore, many studies in both adults and children have shown that different
      ethnicities can result in different pharmacokinetic response to antiretroviral drugs. As a
      result of this, this study investigated the efficacy, safety and pharmacokinetics of
      ATV/r-based HAART in HIV-infected Asian children.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Anticipated">February 2013</completion_date>
  <primary_completion_date type="Anticipated">February 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>pharmacokinetics of atazanavir/ritonavir (ATV/r)</measure>
    <time_frame>48 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Ctrough and Area under the curve (AUC) of atazanavir (ATV) and ritonavir (RTV) will be assessed</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CD4</measure>
    <time_frame>48 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Assess CD percent and count at week 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma viral load (HIV RNA)</measure>
    <time_frame>48 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>assess HIV RNA at week 24 and 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hyperbilirubin</measure>
    <time_frame>48 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>evaluate total and direct bilirubin at weeks 24 and 48</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>PI-experience group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Using PI-based HAART for ≥6 months at the screening visit HIV-RNA viral load &lt; 50 copies/ml at the screening visit No history of HIV-RNA ≥ 1,000 copies/ml while using PI-based HAART</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PI-naïve group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Never been exposed to any PI-containing regimen HIV-RNA viral load ≥ 1,000 copies/ml at the screening visit</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>boosted atazanavir (ATV/r)</intervention_name>
    <description>ATV/r will be taken orally once daily with food plus standard dose of 2 NRTIs according to Thai National HIV treatment guideline</description>
    <arm_group_label>PI-experience group</arm_group_label>
    <arm_group_label>PI-naïve group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. HIV-infected children

          2. Age from 6- 18 years old

          3. Body weight ≥ 25 kg at screening visit

          4. ARV history, the children can be categorized in one of these 2 groups

          5. ALT &lt;200 IU/L at screening visit

          6. Total bilirubin &lt; 3 mg/dL at the screening visit

          7. Can swallow capsule

          8. Written informed consent from caregivers and assent (from children aged 7-17 years
             who know their HIV status)

        Exclusion Criteria:

          1. Active opportunistic infection

          2. Relevant history or current condition, illness that might interfere with
             atazanavir/ritonavir absorption, distribution, metabolism or excretion.

          3. Use of concomitant medication that may interfere with the pharmacokinetics of ATV/r
             (i.e. efavirenz, indinavir, proton pump inhibitor, antacids, cisapride,
             clarithromycin, rifampin etc.)

          4. Pregnancy or lactating at screening visit

          5. Liver diseases e.g. hepatitis B carrier, chronic hepatitis, cirrhosis

          6. Inability to understand the nature and extent of the study and the procedures
             required.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Torsak Bunupuradah, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The HIV Netherlands Australia Thailand Research Collaboration</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Torsak Bunupuradah, MD</last_name>
    <phone>662-652-3040</phone>
    <email>torsak.b@hivnat.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT)</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Torsak Bunupuradah, MD</last_name>
      <phone>662-652-3040</phone>
      <email>torsak.b@hivnat.org</email>
    </contact>
    <contact_backup>
      <last_name>Wasana Prasitsuebsai, MD</last_name>
      <phone>662-652-3040</phone>
      <email>wasana.p@hivnat.org</email>
    </contact_backup>
    <investigator>
      <last_name>Torsak Bunupuradah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Division of Infectious Diseases Department of Pediatrics Faculty of Medicine, Ramathibodi Hospital, Mahidol University</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chonnamet Techasaensiri, MD</last_name>
      <email>chonmet@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Chonnamet Techasaensiri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Pediatrics Faculty of Medicine, Chulalongkorn University</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thanyawee Puthanakit, MD</last_name>
      <phone>662-652-3040</phone>
      <email>thanyawee.p@hivnat.org</email>
    </contact>
    <investigator>
      <last_name>Thanyawee Puthanakit, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <link>
    <url>http://www.hivnat.org</url>
    <description>HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT)</description>
  </link>
  <verification_date>July 2012</verification_date>
  <lastchanged_date>July 31, 2012</lastchanged_date>
  <firstreceived_date>July 17, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pharmacokinetics</keyword>
  <keyword>atazanavir/ritonavir</keyword>
  <keyword>HIV-infected children</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Atazanavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
